Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye implant may delay cataracts after vitrectomy

NCT ID NCT05026632

Disease control Sponsor: Nacuity Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a special implant placed in the eye during vitrectomy surgery to see if it can safely slow down cataract formation. About 30 adults who need vitrectomy and already have some cataract will receive the implant. The goal is to delay cataract progression, possibly reducing the need for future cataract surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2022

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Indicated for vitrectomy 2. Natural Lens in place at time of vitrectomy 3. Some cataract present as assessed pre-operatively Exclusion Criteria: 1. Previous intraocular surgery in study eye. 2. Clear zonular weakness or defects / coloboma. 3. Not on stable dose of medications for other conditions. 4. Need for oral corticosteroids during study participation. 5. Evidence or history of uveitis, or ocular ischemia. 6. Current smoker 7. Use of supplemental oxygen 8. Evidence or history of proliferative diabetic retinopathy. 9. Current lung disease (PU, COPD, Asthma) resulting in decreased oxygen saturation. 10. Sensitivity to thiol compounds. 11. Participation in another clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cataract are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cataract

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cataract

Contacts and locations

Locations

  • Royal Adelaide Hospital

    Adelaide, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.